International Society for Cell & Gene Therapy Stem Cell Engineering Committee report on the current state of hematopoietic stem and progenitor cell–based genomic therapies and the challenges faced

IF 3.2 3区 医学 Q2 BIOTECHNOLOGY & APPLIED MICROBIOLOGY Cytotherapy Pub Date : 2024-11-01 Epub Date: 2024-06-06 DOI:10.1016/j.jcyt.2024.06.002
{"title":"International Society for Cell & Gene Therapy Stem Cell Engineering Committee report on the current state of hematopoietic stem and progenitor cell–based genomic therapies and the challenges faced","authors":"","doi":"10.1016/j.jcyt.2024.06.002","DOIUrl":null,"url":null,"abstract":"<div><div><span><span>Genetic manipulation of hematopoietic stem cells<span> (HSCs) is being developed as a therapeutic strategy for several inherited disorders. This field is rapidly evolving with several novel tools and techniques being employed to achieve desired genetic changes. While commercial products are now available for </span></span>sickle cell disease, transfusion-dependent β-thalassemia, </span>metachromatic leukodystrophy<span> and adrenoleukodystrophy<span>, several challenges remain in patient selection, HSC mobilization and collection, genetic manipulation of stem cells, conditioning, hematologic recovery and post-transplant complications, financial issues, equity of access and institutional and global preparedness. In this report, we explore the current state of development of these therapies and provide a comprehensive assessment of the challenges these therapies face as well as potential solutions.</span></span></div></div>","PeriodicalId":50597,"journal":{"name":"Cytotherapy","volume":"26 11","pages":"Pages 1411-1420"},"PeriodicalIF":3.2000,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Cytotherapy","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S1465324924007357","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/6/6 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"BIOTECHNOLOGY & APPLIED MICROBIOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Genetic manipulation of hematopoietic stem cells (HSCs) is being developed as a therapeutic strategy for several inherited disorders. This field is rapidly evolving with several novel tools and techniques being employed to achieve desired genetic changes. While commercial products are now available for sickle cell disease, transfusion-dependent β-thalassemia, metachromatic leukodystrophy and adrenoleukodystrophy, several challenges remain in patient selection, HSC mobilization and collection, genetic manipulation of stem cells, conditioning, hematologic recovery and post-transplant complications, financial issues, equity of access and institutional and global preparedness. In this report, we explore the current state of development of these therapies and provide a comprehensive assessment of the challenges these therapies face as well as potential solutions.
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
国际细胞与基因治疗学会干细胞工程委员会关于造血干细胞和祖细胞基因组疗法的现状和面临的挑战的报告
对造血干细胞(HSCs)的基因操作正被开发为治疗多种遗传性疾病的一种策略。这一领域发展迅速,目前正采用多种新型工具和技术来实现所需的基因改变。虽然目前已有针对镰状细胞病、输血依赖性β地中海贫血、变色斑性白质营养不良和肾上腺白质营养不良的商业产品,但在患者选择、造血干细胞动员和采集、干细胞遗传操作、调理、血液学恢复和移植后并发症、财务问题、公平获取以及机构和全球准备等方面仍存在一些挑战。在本报告中,我们探讨了这些疗法的发展现状,并对这些疗法面临的挑战和潜在的解决方案进行了全面评估。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
Cytotherapy
Cytotherapy 医学-生物工程与应用微生物
CiteScore
6.30
自引率
4.40%
发文量
683
审稿时长
49 days
期刊介绍: The journal brings readers the latest developments in the fast moving field of cellular therapy in man. This includes cell therapy for cancer, immune disorders, inherited diseases, tissue repair and regenerative medicine. The journal covers the science, translational development and treatment with variety of cell types including hematopoietic stem cells, immune cells (dendritic cells, NK, cells, T cells, antigen presenting cells) mesenchymal stromal cells, adipose cells, nerve, muscle, vascular and endothelial cells, and induced pluripotential stem cells. We also welcome manuscripts on subcellular derivatives such as exosomes. A specific focus is on translational research that brings cell therapy to the clinic. Cytotherapy publishes original papers, reviews, position papers editorials, commentaries and letters to the editor. We welcome "Protocols in Cytotherapy" bringing standard operating procedure for production specific cell types for clinical use within the reach of the readership.
期刊最新文献
Two decades of advancing safe and effective cell-based therapies: a review of the impact, promise, and current limitations of USA regulation 21 CFR Part 1271 Brown adipose–derived mesenchymal stromal cells improve sepsis-induced multiorgan dysfunction more than white adipose cells in obese rats Long-term stability of autologous peripheral blood stem cell products stored for up to 30 years Validated GMP banking of a new set of genomically stable induced pluripotent stem cell lines using single-cell passaging Role of salvage allogeneic transplantation for relapsed or refractory AML in nonremission: insights from real-world practice
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1